FDA Hearing Tuesday: Off-target Risk Concerns for $2M Plus Proposed Genetic Treatment for Sickle Cell
Vertex and Crispr Therapetics working on therapy; California also has sickle cell trial underway
It will be a historic Halloween this week for a couple of companies hoping to turn their genetic experimentation into a successful $2 million-plus treatment for sickle cell disease. At least that is the view of one biotech news outlet.
The matter involves Vertex Pharmaceuticals, Inc., of Boston, and Crispr Therapeutics, of Zug, Switzerland, and an advis…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.